Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model

BACKGROUND: Enhancer of zeste homolog 2 (EZH2) is considered an important driver of tumor development and progression by its histone modifying capabilities. Inhibition of EZH2 activity is thought to be a potent treatment option for eligible cancer patients with an aberrant EZH2 expression profile, t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Akpa, Chidimma Agatha, Kleo, Karsten, Oker, Elisabeth, Tomaszewski, Nancy, Messerschmidt, Clemens, López, Cristina, Wagener, Rabea, Oehl-Huber, Kathrin, Dettmer, Katja, Schoeler, Anne, Lenze, Dido, Oefner, Peter J., Beule, Dieter, Siebert, Reiner, Capper, David, Dimitrova, Lora, Hummel, Michael
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7227222/
https://ncbi.nlm.nih.gov/pubmed/32408898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06937-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires